Vial Logo

Updates

Search
All Resources
Press Releases
Videos
Vial's IL-13 x TSLP Phase 1b study in asthma

Vial Doses First Patient with Asthma in Phase 1b Study of Vial’s IL-13 x TSLP, a Bispecific Antibody Designed for Twice-Yearly Dosing

Vial Doses First Patient for Phase 1 Trial of Vial’s IL-13 x TSLP, a Novel Bispecific Antibody

Read Article

Dr. JiaDe Yu, Chair of Dermatology and Associate Professor at Virginia Commonwealth University School of Medicine, highlights how dual inhibition of IL-13 and TSLP could advance care for patients with atopic dermatitis, delivering stronger efficacy than targeting either pathway alone.

Vial's IL-13 x TSLP Phase 1b study in asthma

Vial Doses First Patient with Asthma in Phase 1b Study of Vial’s IL-13 x TSLP, a Bispecific Antibody Designed for Twice-Yearly Dosing

Vial Doses First Patient for Phase 1 Trial of Vial’s IL-13 x TSLP, a Novel Bispecific Antibody

Read Article

Dr. JiaDe Yu, Chair of Dermatology and Associate Professor at Virginia Commonwealth University School of Medicine, highlights how dual inhibition of IL-13 and TSLP could advance care for patients with atopic dermatitis, delivering stronger efficacy than targeting either pathway alone.

Contact

Information

E: contact@vial.com
S: Linkedin, X

Join our mail list

"*" indicates required fields

Get in touch!

Compose the future with us

"*" indicates required fields

This field is for validation purposes and should be left unchanged.